Last $27.33 USD
Change Today -1.09 / -3.84%
Volume 133.4K
PAHC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

phibro animal health corp-a (PAHC) Snapshot

Open
$28.30
Previous Close
$28.42
Day High
$28.60
Day Low
$27.20
52 Week High
12/8/14 - $33.89
52 Week Low
04/9/14 - $15.00
Market Cap
1.1B
Average Volume 10 Days
184.1K
EPS TTM
$0.94
Shares Outstanding
17.4M
EX-Date
12/1/14
P/E TM
29.0x
Dividend
$0.40
Dividend Yield
0.73%
Current Stock Chart for PHIBRO ANIMAL HEALTH CORP-A (PAHC)

Related News

No related news articles were found.

phibro animal health corp-a (PAHC) Related Businessweek News

No Related Businessweek News Found

phibro animal health corp-a (PAHC) Details

Phibro Animal Health Corporation operates as a diversified developer, manufacturer, and marketer of a range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy, and aquaculture. It also sells specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment offers antibacterials, anticoccidials, and vaccines, which help prevent and manage infectious diseases in livestock and enhance food safety; and nutritional specialty products, which aid the continued health of livestock by enhancing nutrition to help improve health and performance. The Mineral Nutrition segment manufactures and markets approximately 450 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets various specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries, primarily in the United States. The company sells its animal health and mineral nutrition products through local sales offices either directly to integrated poultry, swine, and cattle integrators; or through commercial animal feed manufacturers, wholesalers, and distributors. It sells its performance products through local sales offices to the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey.

1,100 Employees
Last Reported Date: 09/18/14

phibro animal health corp-a (PAHC) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $3.0M
Chief Operating Officer and Director
Total Annual Compensation: $914.7K
President of Animal Health
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

phibro animal health corp-a (PAHC) Key Developments

Phibro Animal Health Corporation Announces Entry Into Collaboration Agreement and License Agreement with MJ Biologicals, Inc

Phibro Animal Health Corporation announced it has acquired exclusive North American distribution rights for vaccines using MJ Biologicals, Inc.'s vaccine technologies focused on the swine industry and additional vaccines that Phibro and MJB intend to develop, pursuant to a collaboration and distribution agreement. In addition, Phibro has acquired exclusive development and distribution rights outside North America for vaccine products using MJB technologies, pursuant to a technology license agreement. Phibro will also acquire certain intellectual property and related assets associated with MJB's vaccine technologies pursuant to an intellectual property acquisition agreement with an expected closing date in January 2021.

Phibro Animal Health Corporation Presents at Bank of America Merrill Lynch 2014 Animal Health Summit, Dec-11-2014 09:50 AM

Phibro Animal Health Corporation Presents at Bank of America Merrill Lynch 2014 Animal Health Summit, Dec-11-2014 09:50 AM. Venue: Bank of America Conference Center, Boston, Massachusetts, United States. Speakers: Jack Clifford Bendheim, Chairman, Chief Executive Officer, President, Member of Compensation Committee and Member of Retirement Benefits Committee, Richard G. Johnson, Chief Financial Officer, Principal Accounting Officer and Member of Retirement Benefits Committee.

Phibro Animal Health Corporation Reports Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Provides Earnings Guidance for the Year Ending June 30, 2015

Phibro Animal Health Corporation reported consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company's net sales of $187.5 million increased $25.2 million, or 16%, for the three months ended September 30, 2014, as compared to the three months ended September 30, 2013, due to growth in Animal Health and Mineral Nutrition of $16.1 million and $9.3 million, respectively. Operating income was $25.1 million against $16.4 million a year ago. Income before income taxes was $22.8 million against $7.0 million a year ago. Net income was $20.5 million or $0.52 per diluted share against $5.8 million or $0.19 per diluted share a year ago. Adjusted EBITDA was $30.5 million against $21.6 million a year ago. EBITDA was $31.7 million against $21.0 million a year ago. Net cash provided by operating activities was $17.4 million against net cash used by operating activities of $0.2 million a year ago. Capital expenditures were $4.0 million against $4.2 million a year ago. On adjusted basis, the company's operating income was $26.2 million against $17.8 million a year ago. Income before income taxes was $22.7 million against $14.4 million a year ago. Net income was $20.2 million or $0.51 per diluted share against $11.8 million or $0.30 per diluted share a year ago. The company has increased its fiscal year ending June 30, 2015 guidance for the benefit of an additional $4 million of licensing revenue and profit for vaccine delivery technology. The revenue was recognized due to the accelerated achievement of a regulatory milestone under an existing license agreement that previously had been expected to occur in its fiscal year 2016. The increase benefits sales and adjusted EBITDA in equal amounts. The company's guidance continues to contemplate an additional $2 million in licensing revenue and profit to be received later 2015 with the final milestone payment to be made under the license agreement, bringing the expected total licensing revenue and profit for the fiscal year to $8 million. Net sales of $739 million to $759 million, representing growth of 7% to 10%, adjusted EBITDA of $103 million to $107 million, representing growth of 14% to 18% and adjusted diluted EPS of $1.57 to $1.62.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PAHC:US $27.33 USD -1.09

PAHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €127.81 EUR -1.75
Novartis AG SFr.90.15 CHF -0.85
Virbac SA €197.20 EUR +0.35
Zoetis Inc $42.73 USD -0.59
View Industry Companies
 

Industry Analysis

PAHC

Industry Average

Valuation PAHC Industry Range
Price/Earnings 81.9x
Price/Sales 1.5x
Price/Book 49.3x
Price/Cash Flow 64.9x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHIBRO ANIMAL HEALTH CORP-A, please visit www.pahc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.